Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 83

1.

Circulating FGF23 is not associated with cardiac dysfunction, atherosclerosis, infection or inflammation in hemodialysis patients.

Takashi Y, Wakino S, Minakuchi H, Ishizu M, Kuroda A, Shima H, Tashiro M, Miya K, Okada K, Minakuchi J, Kawashima S, Matsuhisa M, Matsumoto T, Fukumoto S.

J Bone Miner Metab. 2020 Jan;38(1):70-77. doi: 10.1007/s00774-019-01027-7. Epub 2019 Aug 16.

PMID:
31420749
2.

Pulmonary sarcoidosis as a cause of intermittent fever of unknown origin in a hemodialysis patient with renal cell carcinoma: A case report and literature review.

Shima H, Nishitani M, Tashiro M, Inoue T, Kawahara K, Okada K, Minakuchi J, Kawashima S.

Hemodial Int. 2019 Apr;23(2):E53-E58. doi: 10.1111/hdi.12695. Epub 2019 Feb 7.

PMID:
30729655
3.

Conservative Treatment of Ruptured Thoracoabdominal Aortic Aneurysm in Hemodialysis Patient.

Shima H, Kurushima A, Miya K, Okada K, Minakuchi J, Kawashima S.

J Palliat Med. 2018 Sep;21(9):1206-1207. doi: 10.1089/jpm.2018.0097. No abstract available.

PMID:
30207881
4.

Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients.

Shima H, Miya K, Okada K, Minakuchi J, Kawashima S.

BMC Res Notes. 2018 Jun 8;11(1):363. doi: 10.1186/s13104-018-3483-6.

5.

Intestinal perforation by a peritoneal dialysis catheter in which fungal peritonitis led to diagnosis: a rare case report.

Shima H, Mizoguchi S, Morine Y, Tashiro M, Okada K, Minakuchi J, Kawashima S.

CEN Case Rep. 2018 Nov;7(2):208-210. doi: 10.1007/s13730-018-0328-z. Epub 2018 Apr 2.

6.

Cilostazol-induced acute tubulointerstitial nephritis accompanied by IgA nephropathy: a case report.

Shima H, Tashiro M, Yamada S, Matsuura M, Okada K, Doi T, Minakuchi J, Kawashima S.

BMC Nephrol. 2018 Mar 5;19(1):52. doi: 10.1186/s12882-018-0854-0.

7.

Levocarnitine Injections Decrease the Need for Erythropoiesis-Stimulating Agents in Hemodialysis Patients with Renal Anemia.

Maruyama T, Higuchi T, Yamazaki T, Okawa E, Ando H, Oikawa O, Inoshita A, Okada K, Abe M.

Cardiorenal Med. 2017 Jun;7(3):188-197. doi: 10.1159/000462983. Epub 2017 Apr 20.

8.

Effects of a spleen tyrosine kinase inhibitor on progression of the lupus nephritis in mice.

Kitai M, Fukuda N, Ueno T, Endo M, Maruyama T, Abe M, Okada K, Soma M, Matsumoto K.

J Pharmacol Sci. 2017 May;134(1):29-36. doi: 10.1016/j.jphs.2017.02.015. Epub 2017 Mar 25.

9.

Efficacy and Safety of Pregabalin for the Treatment of Neuropathic Pain in Patients Undergoing Hemodialysis.

Otsuki T, Higuchi T, Yamazaki T, Okawa E, Okada K, Abe M.

Clin Drug Investig. 2017 Jan;37(1):95-102. doi: 10.1007/s40261-016-0464-1.

PMID:
27660209
10.

Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial.

Abe M, Higuchi T, Moriuchi M, Okamura M, Tei R, Nagura C, Takashima H, Kikuchi F, Tomita H, Okada K.

Diabetes Res Clin Pract. 2016 Jun;116:244-52. doi: 10.1016/j.diabres.2016.04.034. Epub 2016 Apr 26.

11.

Retroperitoneal Hematoma in a Patient with Advanced Chronic Kidney Disease Receiving Warfarin Therapy.

Maruyama T, Abe M, Furukawa T, Kobayashi S, Yoshida Y, Noda H, Okada K, Soma M.

Intern Med. 2016;55(9):1153-8. doi: 10.2169/internalmedicine.55.5811. Epub 2016 May 1.

12.

Glycated Albumin versus Glycated Hemoglobin as a Glycemic Indicator in Diabetic Patients on Peritoneal Dialysis.

Kobayashi H, Abe M, Yoshida Y, Suzuki H, Maruyama N, Okada K.

Int J Mol Sci. 2016 Apr 25;17(5). pii: E619. doi: 10.3390/ijms17050619.

13.

Comparison of Clinical Trajectories before Initiation of Renal Replacement Therapy between Diabetic Nephropathy and Nephrosclerosis on the KDIGO Guidelines Heat Map.

Abe M, Okada K, Maruyama N, Takashima H, Oikawa O, Soma M.

J Diabetes Res. 2016;2016:5374746. doi: 10.1155/2016/5374746. Epub 2015 Dec 29.

14.
15.

Levocarnitine Improves Cardiac Function in Hemodialysis Patients With Left Ventricular Hypertrophy: A Randomized Controlled Trial.

Higuchi T, Abe M, Yamazaki T, Okawa E, Ando H, Hotta S, Oikawa O, Kikuchi F, Okada K, Soma M.

Am J Kidney Dis. 2016 Feb;67(2):260-70. doi: 10.1053/j.ajkd.2015.09.010. Epub 2015 Oct 23.

PMID:
26508680
16.

Prevalence of chronic kidney diseases in patients with chronic obstructive pulmonary disease: assessment based on glomerular filtration rate estimated from creatinine and cystatin C levels.

Yoshizawa T, Okada K, Furuichi S, Ishiguro T, Yoshizawa A, Akahoshi T, Gon Y, Akashiba T, Hosokawa Y, Hashimoto S.

Int J Chron Obstruct Pulmon Dis. 2015 Jul 6;10:1283-9. doi: 10.2147/COPD.S80673. eCollection 2015.

17.

A Trial of Pitavastatin Versus Rosuvastatin for Dyslipidemia in Chronic Kidney Disease.

Abe M, Maruyama N, Maruyama T, Okada K, Soma M.

J Atheroscler Thromb. 2015;22(12):1235-47. doi: 10.5551/jat.29264. Epub 2015 Jul 3.

18.

Association of restless legs syndrome with oxidative stress and inflammation in patients undergoing hemodialysis.

Higuchi T, Abe M, Mizuno M, Yamazaki T, Suzuki H, Moriuchi M, Oikawa O, Okawa E, Ando H, Okada K.

Sleep Med. 2015 Aug;16(8):941-8. doi: 10.1016/j.sleep.2015.03.025. Epub 2015 May 8.

PMID:
26070856
19.

Urinary ACE2 is associated with urinary L-FABP and albuminuria in patients with chronic kidney disease.

Abe M, Maruyama N, Oikawa O, Maruyama T, Okada K, Soma M.

Scand J Clin Lab Invest. 2015 Sep;75(5):421-7. doi: 10.3109/00365513.2015.1054871. Epub 2015 Jun 12.

PMID:
26067610
20.

DPP-4 Inhibitors in Diabetic Patients with Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis in Clinical Practice.

Abe M, Okada K.

Contrib Nephrol. 2015;185:98-115. doi: 10.1159/000380974. Epub 2015 May 19. Review.

PMID:
26023019

Supplemental Content

Loading ...
Support Center